ANIX Quote, Financials, Valuation and Earnings

GT Biopharma, Inc. has a net margin of -- compared to Anixa Biosciences, Inc.'s net margin of --. Anixa Biosciences, Inc.'s return on equity of -64.77% beat GT Biopharma, Inc.'s return on equity of -626.24%.

Anixa Biosciences, Inc. has a consensus price target of $10.00, signalling upside risk potential of 212.5%. On the other hand GT Biopharma, Inc. has an analysts' consensus of $8.00 which suggests that it could grow by 861.08%. Given that GT Biopharma, Inc. has higher upside potential than Anixa Biosciences, Inc., analysts believe GT Biopharma, Inc. is more attractive than Anixa Biosciences, Inc..

Anixa Biosciences, Inc. has a beta of 0.488, which suggesting that the stock is 51.221% less volatile than S&P 500. In comparison GT Biopharma, Inc. has a beta of 1.524, suggesting its more volatile than the S&P 500 by 52.367%.

Anixa Biosciences, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. GT Biopharma, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Anixa Biosciences, Inc. pays -- of its earnings as a dividend. GT Biopharma, Inc. pays out -- of its earnings as a dividend.

Anixa Biosciences, Inc. quarterly revenues are --, which are smaller than GT Biopharma, Inc. quarterly revenues of --. Anixa Biosciences, Inc.'s net income of -$2.3M is higher than GT Biopharma, Inc.'s net income of -$3.1M. Notably, Anixa Biosciences, Inc.'s price-to-earnings ratio is -- while GT Biopharma, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Anixa Biosciences, Inc. is -- versus 59.35x for GT Biopharma, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Lexeo Therapeutics, Inc. has a net margin of -- compared to Anixa Biosciences, Inc.'s net margin of --. Anixa Biosciences, Inc.'s return on equity of -64.77% beat Lexeo Therapeutics, Inc.'s return on equity of -86.99%.

Anixa Biosciences, Inc. has a consensus price target of $10.00, signalling upside risk potential of 212.5%. On the other hand Lexeo Therapeutics, Inc. has an analysts' consensus of $19.91 which suggests that it could grow by 94.24%. Given that Anixa Biosciences, Inc. has higher upside potential than Lexeo Therapeutics, Inc., analysts believe Anixa Biosciences, Inc. is more attractive than Lexeo Therapeutics, Inc..

Anixa Biosciences, Inc. has a beta of 0.488, which suggesting that the stock is 51.221% less volatile than S&P 500. In comparison Lexeo Therapeutics, Inc. has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

Anixa Biosciences, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Lexeo Therapeutics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Anixa Biosciences, Inc. pays -- of its earnings as a dividend. Lexeo Therapeutics, Inc. pays out -- of its earnings as a dividend.

Anixa Biosciences, Inc. quarterly revenues are --, which are smaller than Lexeo Therapeutics, Inc. quarterly revenues of --. Anixa Biosciences, Inc.'s net income of -$2.3M is higher than Lexeo Therapeutics, Inc.'s net income of -$20.3M. Notably, Anixa Biosciences, Inc.'s price-to-earnings ratio is -- while Lexeo Therapeutics, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Anixa Biosciences, Inc. is -- versus -- for Lexeo Therapeutics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Merck & Co., Inc. has a net margin of -- compared to Anixa Biosciences, Inc.'s net margin of 33.68%. Anixa Biosciences, Inc.'s return on equity of -64.77% beat Merck & Co., Inc.'s return on equity of 39.63%.

Anixa Biosciences, Inc. has a consensus price target of $10.00, signalling upside risk potential of 212.5%. On the other hand Merck & Co., Inc. has an analysts' consensus of $110.04 which suggests that it could grow by 3.05%. Given that Anixa Biosciences, Inc. has higher upside potential than Merck & Co., Inc., analysts believe Anixa Biosciences, Inc. is more attractive than Merck & Co., Inc..

Anixa Biosciences, Inc. has a beta of 0.488, which suggesting that the stock is 51.221% less volatile than S&P 500. In comparison Merck & Co., Inc. has a beta of 0.294, suggesting its less volatile than the S&P 500 by 70.604%.

Anixa Biosciences, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Merck & Co., Inc. offers a yield of 3.07% to investors and pays a quarterly dividend of $0.85 per share. Anixa Biosciences, Inc. pays -- of its earnings as a dividend. Merck & Co., Inc. pays out 46.32% of its earnings as a dividend. Merck & Co., Inc.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Anixa Biosciences, Inc. quarterly revenues are --, which are smaller than Merck & Co., Inc. quarterly revenues of $17.2B. Anixa Biosciences, Inc.'s net income of -$2.3M is lower than Merck & Co., Inc.'s net income of $5.8B. Notably, Anixa Biosciences, Inc.'s price-to-earnings ratio is -- while Merck & Co., Inc.'s PE ratio is 14.13x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Anixa Biosciences, Inc. is -- versus 4.21x for Merck & Co., Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Puma Biotechnology, Inc. has a net margin of -- compared to Anixa Biosciences, Inc.'s net margin of 16.24%. Anixa Biosciences, Inc.'s return on equity of -64.77% beat Puma Biotechnology, Inc.'s return on equity of 38.49%.

Anixa Biosciences, Inc. has a consensus price target of $10.00, signalling upside risk potential of 212.5%. On the other hand Puma Biotechnology, Inc. has an analysts' consensus of $3.50 which suggests that it could fall by -43.18%. Given that Anixa Biosciences, Inc. has higher upside potential than Puma Biotechnology, Inc., analysts believe Anixa Biosciences, Inc. is more attractive than Puma Biotechnology, Inc..

Anixa Biosciences, Inc. has a beta of 0.488, which suggesting that the stock is 51.221% less volatile than S&P 500. In comparison Puma Biotechnology, Inc. has a beta of 1.177, suggesting its more volatile than the S&P 500 by 17.656%.

Anixa Biosciences, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Puma Biotechnology, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Anixa Biosciences, Inc. pays -- of its earnings as a dividend. Puma Biotechnology, Inc. pays out -- of its earnings as a dividend.

Anixa Biosciences, Inc. quarterly revenues are --, which are smaller than Puma Biotechnology, Inc. quarterly revenues of $54.5M. Anixa Biosciences, Inc.'s net income of -$2.3M is lower than Puma Biotechnology, Inc.'s net income of $8.8M. Notably, Anixa Biosciences, Inc.'s price-to-earnings ratio is -- while Puma Biotechnology, Inc.'s PE ratio is 8.32x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Anixa Biosciences, Inc. is -- versus 1.46x for Puma Biotechnology, Inc.. Usually stocks with elevated PS ratios are considered overvalued.